OSAKA, Japan, April 8, 2026
Shionogi & Co., Ltd. presented new real-world clinical data for Fetroja®/Fetcroja® (cefiderocol) at ESCMID Global 2026, demonstrating strong effectiveness against multidrug-resistant infections, including metallo-beta-lactamase (MBL)-producing Enterobacterales, one of the most critical global health threats.
Real-World Clinical Data Demonstrates Strong Outcomes
The data, derived from the CIRCE study, a multicenter observational analysis conducted in Spain, evaluated 232 adult patients with highly resistant infections. The results showed that 68% of patients achieved clinical cure at day 14, while 83% survival was reported at day 28, highlighting the clinical effectiveness of cefiderocol in real-world settings.
Additionally, clinical response rates reached 82% at day 14, reinforcing the antibiotic’s ability to address infections caused by carbapenem-resistant pathogens, which are often associated with limited treatment options and high mortality rates.
The study population included critically ill patients, with 27% admitted to intensive care units and 13% presenting with septic shock, further emphasizing the significance of these findings in high-risk clinical scenarios. Importantly, no new safety concerns were identified, confirming the established safety profile of cefiderocol.
Advertisement
Addressing Global Antimicrobial Resistance Challenges
MBL-producing Enterobacterales are known to inactivate nearly all beta-lactam antibiotics, including carbapenems, making them a critical priority pathogen group identified by the World Health Organization.
Cefiderocol, a siderophore cephalosporin antibiotic, offers a novel mechanism of action, enabling it to penetrate bacterial cells and overcome resistance mechanisms that limit traditional antibiotics. This positions Fetroja as a key therapeutic option in combating antimicrobial resistance (AMR).
Further data presented at ESCMID 2026 demonstrated high microbiological eradication rates, including 85% in bloodstream infections and 82% in urinary tract infections, reinforcing its effectiveness across multiple infection types.
The study also highlighted the antibiotic’s consistent in vitro activity against resistant pathogens, including Stenotrophomonas maltophilia, with no significant decline in susceptibility observed over a ten-year surveillance period, indicating sustained long-term efficacy.
Expanding Evidence Base for Clinical Practice
The findings contribute to a growing body of real-world evidence (RWE) supporting cefiderocol’s role in treating severe Gram-negative infections, particularly in patients with limited or no alternative treatment options.
Given the increasing burden of antimicrobial resistance globally, these results underscore the importance of continued investment in antibiotic innovation, clinical research, and post-marketing evidence generation.
Shionogi emphasized that real-world clinical data plays a critical role in informing treatment decisions, complementing randomized clinical trials and supporting regulatory and clinical adoption of new therapies.
The ESCMID Global 2026 data presented by Shionogi demonstrate that cefiderocol delivers strong clinical outcomes in real-world settings, offering a valuable treatment option for multidrug-resistant infections. With high cure rates, strong survival outcomes, and sustained antimicrobial activity, Fetroja represents a significant advancement in addressing the global challenge of antimicrobial resistance.
As healthcare systems continue to confront drug-resistant pathogens, innovations like cefiderocol highlight the critical role of pharmaceutical research, clinical validation, and regulatory-driven development in improving patient outcomes and safeguarding global health.
Source: Shionogi press release
